Loading stock data…
ADMA Biologics Inc (ADMA)
$9.54-0.08 (-0.83%)
After Hours$9.54+0.00 (+0.00%)· Last close Sep 8
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ADMA Biologics, Inc. in the Healthcare sector is trading at $9.54 with a market capitalization of $2.2B. Wall Street consensus targets $17.00 (5 analysts), implying a +78.2% move over the next 12 months. The stock is currently near its 52-week low of $7.21, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +78.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $124.39M↑ | $114.49M↓ | $139.16M↑ | $134.22M↑ | $121.98M |
| Gross Profit | $86.28M↑ | $80.75M↓ | $88.82M↑ | $75.63M↑ | $67.23M |
| Operating Income | $52.45M↑ | $50.29M↓ | $62.75M↑ | $51.01M↑ | $42.80M |
| Net Income | $37.82M↓ | $45.33M↓ | $49.38M↑ | $36.43M↑ | $34.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.15B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
41.39%
Volume
Today's trading volume
1.99M
Recent News
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...
ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.
ADMA Biologics Q2 Earnings Call Highlights
ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.